Timely Antiviral Administration During an Influenza Pandemic: Key Components

doi:10.2105/AJPH.2018.304609

. 2018 Sep;108(S3):S215-S220.

doi: 10.2105/AJPH.2018.304609.

Timely Antiviral Administration During an Influenza Pandemic: Key Components

Lisa M Koonin¹, Anita Patel¹

Affiliations

Affiliation

¹ Both authors are with the Influenza Coordination Unit, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA.

PMID: 30192657
PMCID: PMC6129661
DOI: 10.2105/AJPH.2018.304609

Timely Antiviral Administration During an Influenza Pandemic: Key Components

Lisa M Koonin et al. Am J Public Health. 2018 Sep.

. 2018 Sep;108(S3):S215-S220.

doi: 10.2105/AJPH.2018.304609.

Authors

Lisa M Koonin¹, Anita Patel¹

Affiliation

¹ Both authors are with the Influenza Coordination Unit, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA.

PMID: 30192657
PMCID: PMC6129661
DOI: 10.2105/AJPH.2018.304609

Abstract

Prompt treatment of ill persons with influenza antivirals will be an important part of a future pandemic influenza response. This essay reviews key lessons learned from the 2009 H1N1 pandemic and the changing landscape of antiviral drug availability, and identifies and describes the multiple components needed to ensure the timely administration of antiviral drugs during a future pandemic. Fortunately, many of these planning efforts can take place before a pandemic strikes to improve outcomes during a future public health emergency.

PubMed Disclaimer

Figures

**FIGURE 1—**
**Timely Antiviral Treatment During an Influenza Pandemic Depends Upon Success at Every Step**

See this image and copyright information in PMC

Cited by

Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections.
Shahriar I, Kamra M, Kanduluru AK, Campbell CL, Nguyen TH, Srinivasarao M, Low PS. Shahriar I, et al. Proc Natl Acad Sci U S A. 2024 Oct 8;121(41):e2408469121. doi: 10.1073/pnas.2408469121. Epub 2024 Sep 30. Proc Natl Acad Sci U S A. 2024. PMID: 39348541
Factors Influencing the Use and Demand of New Coronavirus Therapy Drugs Among the Adults During COVID-19 in China.
Chen C, Zhang H, Feng X, Wang H. Chen C, et al. Risk Manag Healthc Policy. 2024 Aug 8;17:1937-1945. doi: 10.2147/RMHP.S468700. eCollection 2024. Risk Manag Healthc Policy. 2024. PMID: 39135613 Free PMC article.
At-home testing for respiratory viruses: a minireview of the current landscape.
Smy L, Ledeboer NA, Wood MG. Smy L, et al. J Clin Microbiol. 2024 May 8;62(5):e0031223. doi: 10.1128/jcm.00312-23. Epub 2024 Mar 4. J Clin Microbiol. 2024. PMID: 38436246 Free PMC article. Review.
Genome characterization of influenza A and B viruses in New South Wales, Australia, in 2019: A retrospective study using high-throughput whole genome sequencing.
Wang X, Kim KW, Walker G, Stelzer-Braid S, Scotch M, Rawlinson WD. Wang X, et al. Influenza Other Respir Viruses. 2024 Jan;18(1):e13252. doi: 10.1111/irv.13252. Influenza Other Respir Viruses. 2024. PMID: 38288510 Free PMC article.
The convergent evolution of influenza A virus: Implications, therapeutic strategies and what we need to know.
Low ZY, Wong KH, Wen Yip AJ, Choo WS. Low ZY, et al. Curr Res Microb Sci. 2023 Sep 7;5:100202. doi: 10.1016/j.crmicr.2023.100202. eCollection 2023. Curr Res Microb Sci. 2023. PMID: 37700857 Free PMC article.

See all "Cited by" articles

References

1. Atkins CY, Patel A, Taylor TH, Jr et al. Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Emerg Infect Dis. 2011;17(9):1591–1598. - PMC - PubMed
1. Fry AM, Goswami D, Nahar K et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2014;14(2):109–118. - PubMed
1. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2011;60(1):1–24. - PubMed
1. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009–2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207(4):553–563. - PMC - PubMed
1. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis. 2011;203(1):6–10. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Atkins CY, Patel A, Taylor TH, Jr et al. Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Emerg Infect Dis. 2011;17(9):1591–1598. - PMC - PubMed

[2] Atkins CY, Patel A, Taylor TH, Jr et al. Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Emerg Infect Dis. 2011;17(9):1591–1598. - PMC - PubMed

[3] Fry AM, Goswami D, Nahar K et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2014;14(2):109–118. - PubMed

[4] Fry AM, Goswami D, Nahar K et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2014;14(2):109–118. - PubMed

[5] Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2011;60(1):1–24. - PubMed

[6] Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2011;60(1):1–24. - PubMed

[7] Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009–2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207(4):553–563. - PMC - PubMed

[8] Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009–2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207(4):553–563. - PMC - PubMed

[9] Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis. 2011;203(1):6–10. - PMC - PubMed

[10] Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis. 2011;203(1):6–10. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Timely Antiviral Administration During an Influenza Pandemic: Key Components

Affiliation

Timely Antiviral Administration During an Influenza Pandemic: Key Components

Authors

Affiliation

Abstract

Figures

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical